Leading biopharmaceutical services provider PCI Pharma Services (PCI) has announced further investment in its expansive infrastructure for packaging of controlled substances, complementing its industry-leading capacity for blister packaging, a key tenet of recent calls for dispensing opioid prescriptions in limited quantity unit dose packaging as a tactic to combat substance misuse.
Philadelphia, USA – January 21, 2019 Leading biopharmaceutical services provider PCI Pharma Services (PCI) has announced further investment in its expansive infrastructure for packaging of controlled substances, complementing its industry-leading capacity for blister packaging, a key tenet of recent calls for dispensing opioid prescriptions in limited quantity unit dose packaging as a tactic to combat substance misuse.
PCI has extended onsite controlled substance storage at its US commercial packaging locations in Philadelphia, PA and Rockford, IL, and will undertake further expansions as demand increases for these specialized requirements. PCI supports DEA Schedule I-V controlled substances for both commercial prescription medicines, as well as those for investigational clinical trials, with approximately two million square feet of dedicated packaging infrastructure across the two locations.
Child resistant unit dose blister packaging has been a key focus of discussion in US opioid reform measures. A trusted outsourcing partner to the pharmaceutical industry, PCI features immediate capacity for the introduction of new unit dose blister packaging in formats conducive to meeting the stringent child resistant requirements required by opioids. Specializing in new product introductions, PCI’s extensive capacity positions the company to support more than five billion unit dose blister packs annually.
“There has been considerable discussion about the opportunity for utilizing blister packaging as one tool to positively influence the misuse of opioid and pain management medications in the US,” noted Phil DiGiacomo, Senior Vice President of Sales & Marketing at PCI. “A critical factor in that narrative is to ensure safety in the home. Opioid packaging demands the highest levels of child resistance. PCI is in a unique position to make this specialized packaging immediately available by virtue of our proven, highly automated, high-speed solutions, helping our pharmaceutical clients in their transition to meet the latest legislative requirements. These child resistant packaging solutions protect younger people in the home, and provide an adherence platform supporting the user to take medication as prescribed.”
To hear more about PCI’s investments, visit us here.
About PCI Pharma Services
The global healthcare industry trusts PCI for the development solutions that increase their products’ speed to market and opportunities for commercial success. Only PCI brings the proven experience that comes with more than 50 successful product launches a year and over four decades in the healthcare business. Leading technology and continued investment enables us to address global needs throughout the product life cycle — from preclinical development, clinical investigational studies, commercialization and ongoing supply. Our clients view us as an extension of their business and a collaborative partner, with the shared goal of improving patients’ lives. For more information, please visit www.pciservices.com or follow us on Twitter at@PCI_Social.
Contact
Tom Gosschalk / Claire Oakley at BECG
tom.gosschalk@becg.com / claire.oakley@becg.com
T: +44 (0)20 3697 7647 / +44 (0)1962 893 918
